1228 Stock Overview
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide.
CANbridge Pharmaceuticals Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$1.38|
|52 Week High||HK$3.20|
|52 Week Low||HK$1.30|
|1 Month Change||-14.29%|
|3 Month Change||-16.87%|
|1 Year Change||-52.41%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-84.49%|
Recent News & Updates
|1228||HK Biotechs||HK Market|
Return vs Industry: 1228 underperformed the Hong Kong Biotechs industry which returned 6.4% over the past year.
Return vs Market: 1228 underperformed the Hong Kong Market which returned 1% over the past year.
|1228 Average Weekly Movement||6.6%|
|Biotechs Industry Average Movement||8.0%|
|Market Average Movement||6.5%|
|10% most volatile stocks in HK Market||14.2%|
|10% least volatile stocks in HK Market||3.2%|
Stable Share Price: 1228 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 1228's weekly volatility (7%) has been stable over the past year.
About the Company
|2012||118||James Qun Xue||https://www.canbridgepharma.com|
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, a glycosylation fusion protein that blocks the interaction between the CD95 receptor and its cognate ligand CD95L through binding to CD95L; CAN108, an orally administered small molecule ASBT inhibitor; CAN106, a recombinant human monoclonal antibody that specifically binds to and neutralizes C5 in the complement system; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody; CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid.
CANbridge Pharmaceuticals Inc. Fundamentals Summary
|1228 fundamental statistics|
Is 1228 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1228 income statement (TTM)|
|Cost of Revenue||CN¥33.89m|
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
|Earnings per share (EPS)||-1.07|
|Net Profit Margin||-518.50%|
How did 1228 perform over the long term?See historical performance and comparison